Vlado Perkovic
Vlado Perkovic
Dean of Medicine, University of New South Wales; Professorial Fellow, The George Institute
Verified email at
Cited by
Cited by
Canagliflozin and cardiovascular and renal events in type 2 diabetes
B Neal, V Perkovic, KW Mahaffey, D De Zeeuw, G Fulcher, N Erondu, ...
New England Journal of Medicine 377 (7), 644-657, 2017
Canagliflozin and renal outcomes in type 2 diabetes and nephropathy
V Perkovic, MJ Jardine, B Neal, S Bompoint, HJL Heerspink, ...
New England journal of medicine 380 (24), 2295-2306, 2019
Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials
F Turnbull, B Neal, C Algert, J Chalmers, M Woodward, S MacMahon, ...
Lancet 362 (9395), 1527-1535, 2003
Worldwide access to treatment for end-stage kidney disease: a systematic review
T Liyanage, T Ninomiya, V Jha, B Neal, HM Patrice, I Okpechi, M Zhao, ...
The Lancet 385 (9981), 1975-1982, 2015
Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials
BPLT Trialists’Collaboration
Bmj 336 (7653), 1121-1123, 2008
Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis
M Jun, C Foote, J Lv, B Neal, A Patel, SJ Nicholls, DE Grobbee, A Cass, ...
The Lancet 375 (9729), 1875-1884, 2010
Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis
X Xie, E Atkins, J Lv, A Bennett, B Neal, T Ninomiya, M Woodward, ...
The Lancet 387 (10017), 435-443, 2016
Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes
T Ninomiya, V Perkovic, BE De Galan, S Zoungas, A Pillai, M Jardine, ...
Journal of the American Society of Nephrology 20 (8), 1813-1821, 2009
Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial
J Rosenstock, V Perkovic, OE Johansen, ME Cooper, SE Kahn, N Marx, ...
Jama 321 (1), 69-79, 2019
Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis
CA Emdin, K Rahimi, B Neal, T Callender, V Perkovic, A Patel
Jama 313 (6), 603-615, 2015
Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy
A Levin, M Tonelli, J Bonventre, J Coresh, JA Donner, AB Fogo, CS Fox, ...
The Lancet 390 (10105), 1888-1917, 2017
A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension
MH Olsen, SY Angell, S Asma, P Boutouyrie, D Burger, JA Chirinos, ...
The Lancet 388 (10060), 2665-2712, 2016
Follow-up of blood-pressure lowering and glucose control in type 2 diabetes
S Zoungas, J Chalmers, B Neal, L Billot, Q Li, Y Hirakawa, H Arima, ...
New England Journal of Medicine 371 (15), 1392-1406, 2014
SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
BL Neuen, T Young, HJL Heerspink, B Neal, V Perkovic, L Billot, ...
The lancet Diabetes & endocrinology 7 (11), 845-854, 2019
Chronic kidney disease
K Kalantar-Zadeh, TH Jafar, D Nitsch, BL Neuen, V Perkovic
The lancet 398 (10302), 786-802, 2021
Coffee, decaffeinated coffee, and tea consumption in relation to incident type 2 diabetes mellitus: a systematic review with meta-analysis
R Huxley, CMY Lee, F Barzi, L Timmermeister, S Czernichow, V Perkovic, ...
Archives of internal medicine 169 (22), 2053-2063, 2009
Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data
Blood Pressure Lowering Treatment Trialists' Collaboration
The Lancet 384 (9943), 591-598, 2014
Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
V Perkovic, D de Zeeuw, KW Mahaffey, G Fulcher, N Erondu, W Shaw, ...
The lancet Diabetes & endocrinology 6 (9), 691-704, 2018
Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials
GFM Strippoli, SD Navaneethan, DW Johnson, V Perkovic, F Pellegrini, ...
Bmj 336 (7645), 645-651, 2008
Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study)
KW Mahaffey, B Neal, V Perkovic, D de Zeeuw, G Fulcher, N Erondu, ...
Circulation 137 (4), 323-334, 2018
The system can't perform the operation now. Try again later.
Articles 1–20